Alkem Laboratories Limited

Georgetown University

Kuppuswamy Nagarajan

Shashiprabha

Nagarajan Pattabiraman

Radhakrishnan Padmanabhan

Niklaus Mueller

Kothapalli Sundarraja Rao

Shridhara Kanakamajalu

Govindarajalu Jeyaraman

Sanjay Sukumar Saralaya

Kanakamajalu Shridhara

Debkiron Mukherjee

Akshaya Kunjyannaya

Padmashree Badraje

Veerasamy Ananthalakshmi

K Sundarraja Rao

Sanjay Sukumar Saralya

Shashikumar Hiriyalu Somashekar

Koottungalmadhom Ramaswamy Ranganathan

The present invention relates to atovaquone prodrug compound of formula (I). Accordingly, present invention provides a process involving condensation of Atovaquone (II) with 5-methyl-4-chloromethyl dioxalone (III) in suitable solvent system and optionally followed by distillation and crystallization to provide Atovaquone prodrug compound of formula (I) in high yields, purity, and suitable for large-scale manufacture.

3-(5-methyl-2-oxo-l, 3-dioxol-4-yl) methyloxy-2-trans-[(4-chloro phenyl) cyclohexyl][1,4]naphthaquinone-atovaquone prodrug

Methods of treating, preventing, and/or ameliorating ainfection in a subject are disclosed. The methods comprise administering to the subject a therapeutically effective amount of ainhibitor, e.g., aserine protease inhibitor. These methods are useful in treating, preventing, and/or amelioratinginfections such as, for example, West Nile Virus, Dengue Virus, and Japanese Encephalitis Virus.

Flavivirus inhibitors and methods of their use

Methods of treating, preventing, and/or ameliorating a Flavivirus infection in a subject are disclosed. The methods comprise administering to the subject a therapeutically effective amount of a Flavivirus inhibitor, e.g., a Flavivirus serine protease inhibitor. These methods are useful in treating, preventing, and/or ameliorating Flavivurs infections such as, for example, West Nile Virus, Dengue Virus, and Japanese Encephalitis Virus.

[object Object]

The present invention relates to a process for preparing Ziprasidone of formula I, or a pharmaceutically acceptable salt or a solvate or a hydrate thereof;comprising the steps of reacting 1-(1,2-benzisothiazol-3-yl) piperazine of formula II or its salt: with 5-(2-haloethyl)-6-chloro-oxindole of formula III: wherein X is leaving groups like fluoro, chloro, bromo, iodo or sulphonyl;in the presence of a dispersing agent and a base in a solvent to form ziprasidone of formula I; and optionally converting the ziprasidone formed into a pharmaceutically acceptable acid addition salts of ziprasidone; or a solvate or a hydrate thereof.

Process for the preparation of ziprasidone

The present invention relates the use of 2,3-dihalonaphthoquinone compounds of Formula I wherein Rand Rare leaving groups like halogens selected from the group comprising Cl, Br, I and F and the Rand Rmay be the same halogen or may contain different halogen groups, or sulphonyl groups, for making napthoquinone compounds of Formula IA wherein X is any aryl, heteroaryl, alkyl, cyclohexyl, substituted cylohexyl groups and the like.

Preparation of naphthoquinone compounds using 2,3-dihalonaphthoquinone

Growing community of inventors

Bengaluru, India

Kuppuswamy Nagarajan